Podoplanin: An emerging cancer biomarker and therapeutic target

Harini Krishnan, Julie Rayes, Tomoyuki Miyashita, Genichiro Ishii, Edward P. Retzbach, Stephanie A. Sheehan, Ai Takemoto, Yao Wen Chang, Kazue Yoneda, Jun Asai, Lasse Jensen, Lushun Chalise, Atsushi Natsume, Gary S. Goldberg

Research output: Contribution to journalReview article

37 Scopus citations

Abstract

Podoplanin (PDPN) is a transmembrane receptor glycoprotein that is upregulated on transformed cells, cancer associated fibroblasts and inflammatory macrophages that contribute to cancer progression. In particular, PDPN increases tumor cell clonal capacity, epithelial mesenchymal transition, migration, invasion, metastasis and inflammation. Antibodies, CAR-T cells, biologics and synthetic compounds that target PDPN can inhibit cancer progression and septic inflammation in preclinical models. This review describes recent advances in how PDPN may be used as a biomarker and therapeutic target for many types of cancer, including glioma, squamous cell carcinoma, mesothelioma and melanoma.

Original languageEnglish (US)
Pages (from-to)1292-1299
Number of pages8
JournalCancer Science
Volume109
Issue number5
DOIs
StatePublished - May 2018

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Podoplanin: An emerging cancer biomarker and therapeutic target'. Together they form a unique fingerprint.

  • Cite this

    Krishnan, H., Rayes, J., Miyashita, T., Ishii, G., Retzbach, E. P., Sheehan, S. A., Takemoto, A., Chang, Y. W., Yoneda, K., Asai, J., Jensen, L., Chalise, L., Natsume, A., & Goldberg, G. S. (2018). Podoplanin: An emerging cancer biomarker and therapeutic target. Cancer Science, 109(5), 1292-1299. https://doi.org/10.1111/cas.13580